U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve a new drug for rheumatoid arthritis made by Eli Lilly and Co and partner Incyte Corp, the companies said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Arthritis | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology